Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban

Research output: Contribution to journalArticle

Abstract

Rivaroxaban, which targets factor Xa and does not reduce proteins C/S, was chosen to treat a 6-year-old girl with homozygous protein S (PS) deficiency who developed skin necrosis while on warfarin. Owing to the lack of experience with rivaroxaban in children, the girl was started with 5 mg once-daily, which was gradually increased to 40 mg daily. The increasing dosage was driven by the need to avoid recurrence of skin necrosis. During dose-escalation, four pharmacokinetics assays were carried out measuring drug plasma concentrations and their effect on hemostatic parameters. We report the laboratory work-up, with special reference to parameters of thrombin-generation. Rivaroxaban concentrations by HPLC were correlated with those by the anti-factor Xa assay (r2 = 0.92, p 

Original languageEnglish
Pages (from-to)165-172
Number of pages8
JournalInternational Journal of Hematology
Volume103
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Keywords

  • Anticoagulation
  • Direct oral anticoagulants
  • Purpura fulminans
  • Skin necrosis
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban'. Together they form a unique fingerprint.

  • Cite this